VRTX

NASDAQ · Biotechnology

Vertex Pharmaceuticals Inc

S&P 500 Nasdaq 100 Large-Cap Stocks Blue Chip Stocks Biotech Stocks Healthcare Stocks

$542.62

-4.41 (-0.81%)

As of Nov 12, 9:31 PM ET ·

Financial Highlights (FY 2026)

Revenue

11.66B

Net Income

3.84B

Gross Margin

86.2%

Profit Margin

32.9%

Rev Growth

+10.4%

D/E Ratio

0.01

Revenue & Net Income

Margin Trends

	FY 2026	FY 2025	FY 2024	FY 2023
Gross Margin	86.2%	86.2%	56.9%	56.9%
Operating Margin	34.8%	31.3%	11.0%	10.1%
Profit Margin	32.9%	31.3%	8.5%	11.0%

Income Statement

	FY 2026	FY 2025	FY 2024	FY 2023
Revenue	11.66B	10.57B	15.93B	17.43B
Gross Profit	10.05B	9.11B	9.06B	9.91B
Operating Income	4.05B	3.31B	1.76B	1.76B
Net Income	3.84B	3.13B	1.35B	1.92B
Gross Margin	86.2%	86.2%	56.9%	56.9%
Operating Margin	34.8%	31.3%	11.0%	10.1%
Profit Margin	32.9%	31.3%	8.5%	11.0%
Rev Growth	+10.4%	+10.4%	-6.3%	+21.6%

Balance Sheet

	FY 2026	FY 2025	FY 2024	FY 2023
Total Debt	408.90M	408.90M	13.83B	14.35B
Total Equity	68.15B	68.15B	91.42B	88.18B
D/E Ratio	0.01	0.01	0.15	0.16

Cash Flow

	FY 2026	FY 2025	FY 2024	FY 2023
EBITDA	4.26B	3.67B	2.28B	2.59B
Free Cash Flow	—	—	1.35B	2.40B